Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 1463 entries
View as:

High Quality Evidence of Chinese Lupus Nephritis (HELP)

Phase: N/A Priority: Normal
NCT ID: NCT03001973 Org: User:
Start: 11/30/13 End: 12/31/26 Due: 12/31/27

Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06550921 Org: User:
Start: 08/01/24 End: 08/30/27 Due: 08/30/28

Multi-center Clinical Observation of FCVB in Guangdong Province

Phase: N/A Priority: Normal
NCT ID: NCT03908515 Org: User:
Start: 05/01/19 End: 05/31/20 Due: 05/31/21

Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era

Phase: N/A Priority: Normal
NCT ID: NCT03138642 Org: User:
Start: 07/01/10 End: 05/30/20 Due: 05/30/21

Multimodality Therapy for Palliative Resectable Hepatocellular Carcinoma With Intrahepatic Vessels Invasion

Phase: N/A Priority: Normal
NCT ID: NCT00501813 Org: User:
Start: 10/31/06 End: 07/31/10 Due: 07/31/11

Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing Strategy

Phase: N/A Priority: Normal
NCT ID: NCT01891123 Org: User:
Start: 06/30/13 End: 12/31/16 Due: 12/31/17

Follow-up Strategy for Esophageal Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT06045715 Org: User:
Start: 08/20/22 End: 12/31/23 Due: 12/31/24

A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT

Phase: N/A Priority: Normal
NCT ID: NCT04843267 Org: User:
Start: 05/01/21 End: 05/01/25 Due: 05/01/26

Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00769106 Org: User:
Start: 06/30/08 End: 12/31/14 Due: 12/31/15

Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO

Phase: N/A Priority: Normal
NCT ID: NCT04548284 Org: User:
Start: 05/31/21 End: 12/31/23 Due: 12/31/24

Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02646020 Org: User:
Start: 12/31/15 End: 12/01/20 Due: 12/01/21

Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM

Phase: N/A Priority: Normal
NCT ID: NCT05485909 Org: User:
Start: 07/25/22 End: 06/30/24 Due: 06/30/25

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

Phase: N/A Priority: Normal
NCT ID: NCT06851247 Org: User:
Start: 01/03/25 End: 06/30/27 Due: 06/30/28

Patients With Stage III-IVa Nasopharyngeal Carcinoma With or Without a Mobile Medical Platform Full-course Nutritional Intervention

Phase: N/A Priority: Normal
NCT ID: NCT05834712 Org: User:
Start: 05/11/22 End: 09/24/24 Due: 09/24/25

Artificial Intelligence System for the Detection and Prediction of Kidney Diseases Using Ocular Information

Phase: N/A Priority: Normal
NCT ID: NCT05223712 Org: User:
Start: 08/28/21 End: 12/31/22 Due: 12/31/23

Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01194453 Org: User:
Start: 11/30/09 End: 08/31/12 Due: 08/31/13

Prospective Cohort Study on Prognosis of Patients With Hepatitis B/C

Phase: N/A Priority: Normal
NCT ID: NCT05102838 Org: User:
Start: 11/01/21 End: 03/31/26 Due: 03/31/27

Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02755311 Org: User:
Start: 03/31/14 End: 06/30/16 Due: 06/30/17

WEAR (Wearability and Evaluation of Adjustable Refraction) III

Phase: N/A Priority: Normal
NCT ID: NCT02529540 Org: User:
Start: 09/01/15 End: 06/01/16 Due: 06/01/17

NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.

Phase: N/A Priority: Normal
NCT ID: NCT02347839 Org: User:
Start: 01/01/16 End: 01/01/27 Due: 01/01/28

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05481775 Org: User:
Start: 04/01/22 End: 09/30/25 Due: 09/30/26

The Efficacy and Safety of Ta1 for Sepsis

Phase: N/A Priority: Normal
NCT ID: NCT02867267 Org: User:
Start: 09/06/16 End: 03/23/21 Due: 03/23/22

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06533722 Org: User:
Start: 08/04/24 End: 05/28/25 Due: 05/28/26

Comparison Between Oral and Enema of Chloral Hydrate

Phase: N/A Priority: Normal
NCT ID: NCT03242629 Org: User:
Start: 01/31/17 End: 07/31/17 Due: 07/31/18

SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.

Phase: N/A Priority: Normal
NCT ID: NCT06739317 Org: User:
Start: 01/01/25 End: 06/30/31 Due: 06/30/32